-
1
-
-
0037271306
-
Scientific and therapeutic advances in antiplatelet therapy
-
Bhatt D.L., Topol E.J. Scientific and therapeutic advances in antiplatelet therapy. Nat Rev Drug Discov 2003, 2:15-28.
-
(2003)
Nat Rev Drug Discov
, vol.2
, pp. 15-28
-
-
Bhatt, D.L.1
Topol, E.J.2
-
2
-
-
37249068049
-
Platelet activation and atherothrombosis
-
Davi G., Patrono C. Platelet activation and atherothrombosis. N Engl J Med 2007, 357:2482-2494.
-
(2007)
N Engl J Med
, vol.357
, pp. 2482-2494
-
-
Davi, G.1
Patrono, C.2
-
3
-
-
40749114795
-
Signal-dependent protein synthesis by activated platelets: new pathways to altered phenotype and function
-
Zimmerman G.A., Weyrich A.S. Signal-dependent protein synthesis by activated platelets: new pathways to altered phenotype and function. Arterioscler Thromb Vasc Biol 2008, 28:s17-s24.
-
(2008)
Arterioscler Thromb Vasc Biol
, vol.28
-
-
Zimmerman, G.A.1
Weyrich, A.S.2
-
4
-
-
78650415748
-
Signaling during platelet adhesion and activation
-
Li Z., Delaney M.K., O'Brien K.A., Du X. Signaling during platelet adhesion and activation. Arterioscler Thromb Vasc Biol 2010, 30:2341-2349.
-
(2010)
Arterioscler Thromb Vasc Biol
, vol.30
, pp. 2341-2349
-
-
Li, Z.1
Delaney, M.K.2
O'Brien, K.A.3
Du, X.4
-
5
-
-
0025006615
-
Atherosclerotic plaque rupture and thrombosis. Evolving concepts
-
Fuster V., Stein B., Ambrose J.A., Badimon L., Badimon J.J., Chesebro J.H. Atherosclerotic plaque rupture and thrombosis. Evolving concepts. Circulation 1990, 82:II47-II59.
-
(1990)
Circulation
, vol.82
-
-
Fuster, V.1
Stein, B.2
Ambrose, J.A.3
Badimon, L.4
Badimon, J.J.5
Chesebro, J.H.6
-
6
-
-
0037180771
-
Inflammation in atherosclerosis
-
Libby P. Inflammation in atherosclerosis. Nature 2002, 420:868-874.
-
(2002)
Nature
, vol.420
, pp. 868-874
-
-
Libby, P.1
-
7
-
-
50449098285
-
Mechanisms of thrombus formation
-
Furie B., Furie B.C. Mechanisms of thrombus formation. N Engl J Med 2008, 359:938-949.
-
(2008)
N Engl J Med
, vol.359
, pp. 938-949
-
-
Furie, B.1
Furie, B.C.2
-
8
-
-
0023805341
-
Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2
-
ISIS-2 (Second International Study of Infarct Survival) Collaborative Group
-
Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988, 2:349-360. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group.
-
(1988)
Lancet
, vol.2
, pp. 349-360
-
-
-
9
-
-
78751616421
-
Antiplatelet therapy in coronary heart disease prevention
-
Kolandaivelu K., Bhatt D.L. Antiplatelet therapy in coronary heart disease prevention. Cardiol Clin 2011, 29:71-85.
-
(2011)
Cardiol Clin
, vol.29
, pp. 71-85
-
-
Kolandaivelu, K.1
Bhatt, D.L.2
-
10
-
-
77953676517
-
Antiplatelet therapy after percutaneous coronary intervention: Should another regimen be "TAPT?"
-
Croce K. Antiplatelet therapy after percutaneous coronary intervention: Should another regimen be "TAPT?". Circ Cardiovasc Interv 2010, 3:3-5.
-
(2010)
Circ Cardiovasc Interv
, vol.3
, pp. 3-5
-
-
Croce, K.1
-
11
-
-
77649126524
-
Heart disease and stroke statistics-2010 update: a report from the American Heart Association
-
Lloyd-Jones D., Adams R.J., Brown T.M., Carnethon M., Dai S., De Simone G., et al. Heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation 2010, 121:e46-e215.
-
(2010)
Circulation
, vol.121
-
-
Lloyd-Jones, D.1
Adams, R.J.2
Brown, T.M.3
Carnethon, M.4
Dai, S.5
De Simone, G.6
-
12
-
-
79959550517
-
Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium
-
Mehran R., Rao S.V., Bhatt D.L., Gibson C.M., Caixeta A., Eikelboom J., et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation 2011, 123:2736-2747.
-
(2011)
Circulation
, vol.123
, pp. 2736-2747
-
-
Mehran, R.1
Rao, S.V.2
Bhatt, D.L.3
Gibson, C.M.4
Caixeta, A.5
Eikelboom, J.6
-
13
-
-
36148940945
-
Intensifying platelet inhibition-navigating between Scylla and Charybdis
-
Bhatt D.L. Intensifying platelet inhibition-navigating between Scylla and Charybdis. N Engl J Med 2007, 357:2078-2081.
-
(2007)
N Engl J Med
, vol.357
, pp. 2078-2081
-
-
Bhatt, D.L.1
-
14
-
-
77958005516
-
Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial
-
Mehta S.R., Tanguay J.F., Eikelboom J.W., Jolly S.S., Joyner C.D., Granger C.B., et al. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet 2010, 376:1233-1243.
-
(2010)
Lancet
, vol.376
, pp. 1233-1243
-
-
Mehta, S.R.1
Tanguay, J.F.2
Eikelboom, J.W.3
Jolly, S.S.4
Joyner, C.D.5
Granger, C.B.6
-
15
-
-
34248352504
-
Aspirin dose for the prevention of cardiovascular disease: a systematic review
-
Campbell C.L., Smyth S., Montalescot G., Steinhubl S.R. Aspirin dose for the prevention of cardiovascular disease: a systematic review. JAMA 2007, 297:2018-2024.
-
(2007)
JAMA
, vol.297
, pp. 2018-2024
-
-
Campbell, C.L.1
Smyth, S.2
Montalescot, G.3
Steinhubl, S.R.4
-
16
-
-
38949153807
-
Historical review: megakaryopoiesis and thrombopoiesis
-
Kaushansky K. Historical review: megakaryopoiesis and thrombopoiesis. Blood 2008, 111:981-986.
-
(2008)
Blood
, vol.111
, pp. 981-986
-
-
Kaushansky, K.1
-
17
-
-
0025020549
-
Platelets, blood flow, and the vessel wall
-
discussion I40-21.
-
Mustard J.F., Packham M.A., Kinlough-Rathbone R.L. Platelets, blood flow, and the vessel wall. Circulation 1990, 81:I24-I27. discussion I40-21.
-
(1990)
Circulation
, vol.81
-
-
Mustard, J.F.1
Packham, M.A.2
Kinlough-Rathbone, R.L.3
-
18
-
-
79954633893
-
Stent thrombogenicity early in high-risk interventional settings is driven by stent design and deployment and protected by polymer-drug coatings
-
Kolandaivelu K., Swaminathan R., Gibson W.J., Kolachalama V.B., Nguyen-Ehrenreich K.L., Giddings V.L., et al. Stent thrombogenicity early in high-risk interventional settings is driven by stent design and deployment and protected by polymer-drug coatings. Circulation 2011, 123:1400-1409.
-
(2011)
Circulation
, vol.123
, pp. 1400-1409
-
-
Kolandaivelu, K.1
Swaminathan, R.2
Gibson, W.J.3
Kolachalama, V.B.4
Nguyen-Ehrenreich, K.L.5
Giddings, V.L.6
-
19
-
-
0032483550
-
Specific synergy of multiple substrate-receptor interactions in platelet thrombus formation under flow
-
Savage B., Almus-Jacobs F., Ruggeri Z.M. Specific synergy of multiple substrate-receptor interactions in platelet thrombus formation under flow. Cell 1998, 94:657-666.
-
(1998)
Cell
, vol.94
, pp. 657-666
-
-
Savage, B.1
Almus-Jacobs, F.2
Ruggeri, Z.M.3
-
20
-
-
0036851876
-
Platelets in atherothrombosis
-
Ruggeri Z.M. Platelets in atherothrombosis. Nat Med 2002, 8:1227-1234.
-
(2002)
Nat Med
, vol.8
, pp. 1227-1234
-
-
Ruggeri, Z.M.1
-
21
-
-
0034066977
-
Old concepts and new developments in the study of platelet aggregation
-
Ruggeri Z.M. Old concepts and new developments in the study of platelet aggregation. J Clin Invest 2000, 105:699-701.
-
(2000)
J Clin Invest
, vol.105
, pp. 699-701
-
-
Ruggeri, Z.M.1
-
22
-
-
0036090365
-
Shear-dependent tether formation during platelet translocation on von Willebrand factor
-
Dopheide S.M., Maxwell M.J., Jackson S.P. Shear-dependent tether formation during platelet translocation on von Willebrand factor. Blood 2002, 99:159-167.
-
(2002)
Blood
, vol.99
, pp. 159-167
-
-
Dopheide, S.M.1
Maxwell, M.J.2
Jackson, S.P.3
-
23
-
-
0038494921
-
Platelet-collagen interaction: Is GPVI the central receptor?
-
Nieswandt B., Watson S.P. Platelet-collagen interaction: Is GPVI the central receptor?. Blood 2003, 102:449-461.
-
(2003)
Blood
, vol.102
, pp. 449-461
-
-
Nieswandt, B.1
Watson, S.P.2
-
24
-
-
75949128633
-
Antiplatelet therapies for the treatment of cardiovascular disease
-
Michelson A.D. Antiplatelet therapies for the treatment of cardiovascular disease. Nat Rev Drug Discov 2010, 9:154-169.
-
(2010)
Nat Rev Drug Discov
, vol.9
, pp. 154-169
-
-
Michelson, A.D.1
-
25
-
-
17444444169
-
A revised model of platelet aggregation
-
Kulkarni S., Dopheide S.M., Yap C.L., Ravanat C., Freund M., Mangin P., et al. A revised model of platelet aggregation. J Clin Invest 2000, 105:783-791.
-
(2000)
J Clin Invest
, vol.105
, pp. 783-791
-
-
Kulkarni, S.1
Dopheide, S.M.2
Yap, C.L.3
Ravanat, C.4
Freund, M.5
Mangin, P.6
-
26
-
-
0035824895
-
CD40 signaling and plaque instability
-
Schonbeck U., Libby P. CD40 signaling and plaque instability. Circ Res 2001, 89:1092-1103.
-
(2001)
Circ Res
, vol.89
, pp. 1092-1103
-
-
Schonbeck, U.1
Libby, P.2
-
27
-
-
28244459634
-
Low-dose aspirin for the prevention of atherothrombosis
-
Patrono C., Garcia Rodriguez L.A., Landolfi R., Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 2005, 353:2373-2383.
-
(2005)
N Engl J Med
, vol.353
, pp. 2373-2383
-
-
Patrono, C.1
Garcia Rodriguez, L.A.2
Landolfi, R.3
Baigent, C.4
-
28
-
-
0037065502
-
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
-
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86.
-
(2002)
BMJ
, vol.324
, pp. 71-86
-
-
-
29
-
-
46049108934
-
Antiplatelet drugs: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition)
-
Patrono C., Baigent C., Hirsh J., Roth G. Antiplatelet drugs: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008, 133:199S-233S.
-
(2008)
Chest
, vol.133
-
-
Patrono, C.1
Baigent, C.2
Hirsh, J.3
Roth, G.4
-
30
-
-
65849268320
-
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials
-
Baigent C., Blackwell L., Collins R., Emberson J., Godwin J., Peto R., et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009, 373:1849-1860.
-
(2009)
Lancet
, vol.373
, pp. 1849-1860
-
-
Baigent, C.1
Blackwell, L.2
Collins, R.3
Emberson, J.4
Godwin, J.5
Peto, R.6
-
31
-
-
84882712809
-
Glycoprotein IIb/IIIa antagonists. Development of abciximab and pharmacology of abciximab, tirofiban, and eptifibatide
-
Humana Press, Totowa, NJ, A.M. Lincoff (Ed.)
-
Coller B.S. Glycoprotein IIb/IIIa antagonists. Development of abciximab and pharmacology of abciximab, tirofiban, and eptifibatide. Platelet Glycoprotein IIb/IIIa Inhibitors in Cardiovascular Disease 2003, 73-101. Humana Press, Totowa, NJ. A.M. Lincoff (Ed.).
-
(2003)
Platelet Glycoprotein IIb/IIIa Inhibitors in Cardiovascular Disease
, pp. 73-101
-
-
Coller, B.S.1
-
32
-
-
80053289254
-
The evolution of antiplatelet therapy in cardiovascular disease
-
Yousuf O., Bhatt D.L. The evolution of antiplatelet therapy in cardiovascular disease. Nat Rev Cardiol 2011, 8(10):547-559.
-
(2011)
Nat Rev Cardiol
, vol.8
, Issue.10
, pp. 547-559
-
-
Yousuf, O.1
Bhatt, D.L.2
-
33
-
-
0037005777
-
Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting
-
Bhatt D.L., Bertrand M.E., Berger P.B., L'Allier P.L., Moussa I., Moses J.W., et al. Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting. J Am Coll Cardiol 2002, 39:9-14.
-
(2002)
J Am Coll Cardiol
, vol.39
, pp. 9-14
-
-
Bhatt, D.L.1
Bertrand, M.E.2
Berger, P.B.3
L'Allier, P.L.4
Moussa, I.5
Moses, J.W.6
-
34
-
-
77955013649
-
Overcoming "resistance" to antiplatelet therapy: targeting the issue of nonadherence
-
Kolandaivelu K., Bhatt D.L. Overcoming "resistance" to antiplatelet therapy: targeting the issue of nonadherence. Nat Rev Cardiol 2010, 7:461-467.
-
(2010)
Nat Rev Cardiol
, vol.7
, pp. 461-467
-
-
Kolandaivelu, K.1
Bhatt, D.L.2
-
35
-
-
0030590746
-
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)
-
CAPRIE Steering Committee A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996, 348:1329-1339.
-
(1996)
Lancet
, vol.348
, pp. 1329-1339
-
-
CAPRIE Steering Committee1
-
36
-
-
0035899289
-
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation
-
Yusuf S., Zhao F., Mehta S.R., Chrolavicius S., Tognoni G., Fox K.K. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001, 345:494-502.
-
(2001)
N Engl J Med
, vol.345
, pp. 494-502
-
-
Yusuf, S.1
Zhao, F.2
Mehta, S.R.3
Chrolavicius, S.4
Tognoni, G.5
Fox, K.K.6
-
37
-
-
0035908781
-
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study
-
Mehta S.R., Yusuf S., Peters R.J., Bertrand M.E., Lewis B.S., Natarajan M.K., et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001, 358:527-533.
-
(2001)
Lancet
, vol.358
, pp. 527-533
-
-
Mehta, S.R.1
Yusuf, S.2
Peters, R.J.3
Bertrand, M.E.4
Lewis, B.S.5
Natarajan, M.K.6
-
38
-
-
33645861080
-
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events
-
Bhatt D.L., Fox K.A., Hacke W., Berger P.B., Black H.R., Boden W.E., et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006, 354:1706-1717.
-
(2006)
N Engl J Med
, vol.354
, pp. 1706-1717
-
-
Bhatt, D.L.1
Fox, K.A.2
Hacke, W.3
Berger, P.B.4
Black, H.R.5
Boden, W.E.6
-
39
-
-
34247869852
-
Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial
-
Bhatt D.L., Flather M.D., Hacke W., Berger P.B., Black H.R., Boden W.E., et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol 2007, 49:1982-1988.
-
(2007)
J Am Coll Cardiol
, vol.49
, pp. 1982-1988
-
-
Bhatt, D.L.1
Flather, M.D.2
Hacke, W.3
Berger, P.B.4
Black, H.R.5
Boden, W.E.6
-
40
-
-
36148983750
-
Prasugrel versus clopidogrel in patients with acute coronary syndromes
-
Wiviott S.D., Braunwald E., McCabe C.H., Montalescot G., Ruzyllo W., Gottlieb S., et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007, 357:2001-2015.
-
(2007)
N Engl J Med
, vol.357
, pp. 2001-2015
-
-
Wiviott, S.D.1
Braunwald, E.2
McCabe, C.H.3
Montalescot, G.4
Ruzyllo, W.5
Gottlieb, S.6
-
41
-
-
27744516843
-
Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose between 3 High oral doses for Immediate Clopidogrel Effect) trial
-
von Beckerath N., Taubert D., Pogatsa-Murray G., Schomig E., Kastrati A., Schomig A. Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose between 3 High oral doses for Immediate Clopidogrel Effect) trial. Circulation 2005, 112:2946-2950.
-
(2005)
Circulation
, vol.112
, pp. 2946-2950
-
-
von Beckerath, N.1
Taubert, D.2
Pogatsa-Murray, G.3
Schomig, E.4
Kastrati, A.5
Schomig, A.6
-
42
-
-
37349111065
-
Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the prasugrel in comparison to clopidogrel for inhibition of platelet activation and aggregation-thrombolysis in myocardial infarction 44 trial
-
Wiviott S.D., Trenk D., Frelinger A.L., O'Donoghue M., Neumann F.J., Michelson A.D., et al. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the prasugrel in comparison to clopidogrel for inhibition of platelet activation and aggregation-thrombolysis in myocardial infarction 44 trial. Circulation 2007, 116:2923-2932.
-
(2007)
Circulation
, vol.116
, pp. 2923-2932
-
-
Wiviott, S.D.1
Trenk, D.2
Frelinger, A.L.3
O'Donoghue, M.4
Neumann, F.J.5
Michelson, A.D.6
-
43
-
-
33646596912
-
Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial
-
Halkes P.H., van Gijn J., Kappelle L.J., Koudstaal P.J., Algra A. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet 2006, 367:1665-1673.
-
(2006)
Lancet
, vol.367
, pp. 1665-1673
-
-
Halkes, P.H.1
van Gijn, J.2
Kappelle, L.J.3
Koudstaal, P.J.4
Algra, A.5
-
44
-
-
51449116270
-
Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke
-
Sacco R.L., Diener H.C., Yusuf S., Cotton D., Ounpuu S., Lawton W.A., et al. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med 2008, 359:1238-1251.
-
(2008)
N Engl J Med
, vol.359
, pp. 1238-1251
-
-
Sacco, R.L.1
Diener, H.C.2
Yusuf, S.3
Cotton, D.4
Ounpuu, S.5
Lawton, W.A.6
-
45
-
-
78650097647
-
Rationale and design of the dual antiplatelet therapy study, a prospective, multicenter, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing percutaneous coronary intervention with either drug-eluting stent or bare metal stent placement for the treatment of coronary artery lesions
-
1041 e1031.
-
Mauri L., Kereiakes D.J., Normand S.L., Wiviott S.D., Cohen D.J., Holmes D.R., et al. Rationale and design of the dual antiplatelet therapy study, a prospective, multicenter, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing percutaneous coronary intervention with either drug-eluting stent or bare metal stent placement for the treatment of coronary artery lesions. Am Heart J 2010, 160:1035-1041. 1041 e1031.
-
(2010)
Am Heart J
, vol.160
, pp. 1035-1041
-
-
Mauri, L.1
Kereiakes, D.J.2
Normand, S.L.3
Wiviott, S.D.4
Cohen, D.J.5
Holmes, D.R.6
-
46
-
-
66149124479
-
Early versus delayed, provisional eptifibatide in acute coronary syndromes
-
Giugliano R.P., White J.A., Bode C., Armstrong P.W., Montalescot G., Lewis B.S., et al. Early versus delayed, provisional eptifibatide in acute coronary syndromes. N Engl J Med 2009, 360:2176-2190.
-
(2009)
N Engl J Med
, vol.360
, pp. 2176-2190
-
-
Giugliano, R.P.1
White, J.A.2
Bode, C.3
Armstrong, P.W.4
Montalescot, G.5
Lewis, B.S.6
-
47
-
-
37349035313
-
Late coronary stent thrombosis
-
Windecker S., Meier B. Late coronary stent thrombosis. Circulation 2007, 116:1952-1965.
-
(2007)
Circulation
, vol.116
, pp. 1952-1965
-
-
Windecker, S.1
Meier, B.2
-
48
-
-
77950249728
-
Bridging the gap between clinical trials of antiplatelet therapies and applications among elderly patients
-
e501.
-
Dauerman H.L., Bhatt D.L., Gretler D.D., French P.A., Smyth S.S., Becker R.C. Bridging the gap between clinical trials of antiplatelet therapies and applications among elderly patients. Am Heart J 2010, 159:508-517. e501.
-
(2010)
Am Heart J
, vol.159
, pp. 508-517
-
-
Dauerman, H.L.1
Bhatt, D.L.2
Gretler, D.D.3
French, P.A.4
Smyth, S.S.5
Becker, R.C.6
-
49
-
-
77953395570
-
Representation of women in randomized clinical trials of cardiovascular disease prevention
-
Melloni C., Berger J.S., Wang T.Y., Gunes F., Stebbins A., Pieper K.S., et al. Representation of women in randomized clinical trials of cardiovascular disease prevention. Circ Cardiovasc Qual Outcomes 2010, 3:135-142.
-
(2010)
Circ Cardiovasc Qual Outcomes
, vol.3
, pp. 135-142
-
-
Melloni, C.1
Berger, J.S.2
Wang, T.Y.3
Gunes, F.4
Stebbins, A.5
Pieper, K.S.6
-
50
-
-
69249219295
-
Tailoring antiplatelet therapy based on pharmacogenomics: How well do the data fit?
-
Bhatt D.L. Tailoring antiplatelet therapy based on pharmacogenomics: How well do the data fit?. JAMA 2009, 302:896-897.
-
(2009)
JAMA
, vol.302
, pp. 896-897
-
-
Bhatt, D.L.1
-
51
-
-
58749094444
-
Cytochrome P-450 polymorphisms and response to clopidogrel
-
Mega J.L., Close S.L., Wiviott S.D., Shen L., Hockett R.D., Brandt J.T., et al. Cytochrome P-450 polymorphisms and response to clopidogrel. N Engl J Med 2009, 360:354-362.
-
(2009)
N Engl J Med
, vol.360
, pp. 354-362
-
-
Mega, J.L.1
Close, S.L.2
Wiviott, S.D.3
Shen, L.4
Hockett, R.D.5
Brandt, J.T.6
-
52
-
-
69249219296
-
Association of cytochrome P450 2c19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy
-
Shuldiner A.R., O'Connell J.R., Bliden K.P., Gandhi A., Ryan K., Horenstein R.B., et al. Association of cytochrome P450 2c19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 2009, 302:849-857.
-
(2009)
JAMA
, vol.302
, pp. 849-857
-
-
Shuldiner, A.R.1
O'Connell, J.R.2
Bliden, K.P.3
Gandhi, A.4
Ryan, K.5
Horenstein, R.B.6
-
53
-
-
76349098199
-
Cytochrome 2c19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement
-
Sibbing D., Koch W., Gebhard D., Schuster T., Braun S., Stegherr J., et al. Cytochrome 2c19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation 2010, 121:512-518.
-
(2010)
Circulation
, vol.121
, pp. 512-518
-
-
Sibbing, D.1
Koch, W.2
Gebhard, D.3
Schuster, T.4
Braun, S.5
Stegherr, J.6
-
54
-
-
58749090547
-
Genetic determinants of response to clopidogrel and cardiovascular events
-
Simon T., Verstuyft C., Mary-Krause M., Quteineh L., Drouet E., Meneveau N., et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009, 360:363-375.
-
(2009)
N Engl J Med
, vol.360
, pp. 363-375
-
-
Simon, T.1
Verstuyft, C.2
Mary-Krause, M.3
Quteineh, L.4
Drouet, E.5
Meneveau, N.6
-
55
-
-
67649654260
-
Antiplatelet drug "resistance". Part 1: mechanisms and clinical measurements
-
Sweeny J.M., Gorog D.A., Fuster V. Antiplatelet drug "resistance". Part 1: mechanisms and clinical measurements. Nat Rev Cardiol 2009, 6:273-282.
-
(2009)
Nat Rev Cardiol
, vol.6
, pp. 273-282
-
-
Sweeny, J.M.1
Gorog, D.A.2
Fuster, V.3
-
56
-
-
67651173161
-
Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON TIMI-38 trial
-
Michelson A.D., Frelinger A.L., Braunwald E., Downey W.E., Angiolillo D.J., Xenopoulos N.P., et al. Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON TIMI-38 trial. Eur Heart J 2009, 30:1753-1763.
-
(2009)
Eur Heart J
, vol.30
, pp. 1753-1763
-
-
Michelson, A.D.1
Frelinger, A.L.2
Braunwald, E.3
Downey, W.E.4
Angiolillo, D.J.5
Xenopoulos, N.P.6
-
57
-
-
11844256436
-
Variability in platelet responsiveness to clopidogrel among 544 individuals
-
Serebruany V.L., Steinhubl S.R., Berger P.B., Malinin A.I., Bhatt D.L., Topol E.J. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 2005, 45:246-251.
-
(2005)
J Am Coll Cardiol
, vol.45
, pp. 246-251
-
-
Serebruany, V.L.1
Steinhubl, S.R.2
Berger, P.B.3
Malinin, A.I.4
Bhatt, D.L.5
Topol, E.J.6
-
58
-
-
77249113768
-
Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation
-
Breet N.J., van Werkum J.W., Bouman H.J., Kelder J.C., Ruven H.J., Bal E.T., et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA 2010, 303:754-762.
-
(2010)
JAMA
, vol.303
, pp. 754-762
-
-
Breet, N.J.1
van Werkum, J.W.2
Bouman, H.J.3
Kelder, J.C.4
Ruven, H.J.5
Bal, E.T.6
-
59
-
-
58149476444
-
Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis
-
Bonello L., Camoin-Jau L., Armero S., Com O., Arques S., Burignat-Bonello C., et al. Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis. Am J Cardiol 2009, 103:5-10.
-
(2009)
Am J Cardiol
, vol.103
, pp. 5-10
-
-
Bonello, L.1
Camoin-Jau, L.2
Armero, S.3
Com, O.4
Arques, S.5
Burignat-Bonello, C.6
-
60
-
-
80052573217
-
Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the gauging responsiveness with a VerifyNow P2Y12 assay: impact on thrombosis and safety (GRAVITAS) trial
-
Price M.J., Angiolillo D.J., Teirstein P.S., Lillie E., Manoukian S.V., Berger P.B., et al. Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the gauging responsiveness with a VerifyNow P2Y12 assay: impact on thrombosis and safety (GRAVITAS) trial. Circulation 2011, 124:1132-1137.
-
(2011)
Circulation
, vol.124
, pp. 1132-1137
-
-
Price, M.J.1
Angiolillo, D.J.2
Teirstein, P.S.3
Lillie, E.4
Manoukian, S.V.5
Berger, P.B.6
-
62
-
-
75549086129
-
Antiplatelet therapy: Ticagrelor in ACS-what does PLATO teach us?
-
Bhatt D.L. Antiplatelet therapy: Ticagrelor in ACS-what does PLATO teach us?. Nat Rev Cardiol 2009, 6:737-738.
-
(2009)
Nat Rev Cardiol
, vol.6
, pp. 737-738
-
-
Bhatt, D.L.1
-
63
-
-
70149101223
-
Ticagrelor versus clopidogrel in patients with acute coronary syndromes
-
Wallentin L., Becker R.C., Budaj A., Cannon C.P., Emanuelsson H., Held C., et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009, 361:1045-1057.
-
(2009)
N Engl J Med
, vol.361
, pp. 1045-1057
-
-
Wallentin, L.1
Becker, R.C.2
Budaj, A.3
Cannon, C.P.4
Emanuelsson, H.5
Held, C.6
-
64
-
-
71849087338
-
Platelet inhibition with cangrelor in patients undergoing PCI
-
Harrington R.A., Stone G.W., McNulty S., White H.D., Lincoff A.M., Gibson C.M., et al. Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med 2009, 361:2318-2329.
-
(2009)
N Engl J Med
, vol.361
, pp. 2318-2329
-
-
Harrington, R.A.1
Stone, G.W.2
McNulty, S.3
White, H.D.4
Lincoff, A.M.5
Gibson, C.M.6
-
65
-
-
71849119604
-
Intravenous platelet blockade with cangrelor during PCI
-
Bhatt D.L., Lincoff A.M., Gibson C.M., Stone G.W., McNulty S., Montalescot G., et al. Intravenous platelet blockade with cangrelor during PCI. N Engl J Med 2009, 361:2330-2341.
-
(2009)
N Engl J Med
, vol.361
, pp. 2330-2341
-
-
Bhatt, D.L.1
Lincoff, A.M.2
Gibson, C.M.3
Stone, G.W.4
McNulty, S.5
Montalescot, G.6
-
66
-
-
77955677366
-
Rationale and design of the randomized, double-blind trial testing intravenous and oral administration of elinogrel, a selective and reversible P2Y(12)-receptor inhibitor, versus clopidogrel to evaluate tolerability and efficacy in nonurgent percutaneous coronary interventions patients (INNOVATE-pci)
-
Leonardi S., Rao S.V., Harrington R.A., Bhatt D.L., Gibson C.M., Roe M.T., et al. Rationale and design of the randomized, double-blind trial testing intravenous and oral administration of elinogrel, a selective and reversible P2Y(12)-receptor inhibitor, versus clopidogrel to evaluate tolerability and efficacy in nonurgent percutaneous coronary interventions patients (INNOVATE-pci). Am Heart J 2010, 160:65-72.
-
(2010)
Am Heart J
, vol.160
, pp. 65-72
-
-
Leonardi, S.1
Rao, S.V.2
Harrington, R.A.3
Bhatt, D.L.4
Gibson, C.M.5
Roe, M.T.6
-
67
-
-
84856293074
-
12 inhibitor, in non-urgent pci (abstract 2036)
-
12 inhibitor, in non-urgent pci (abstract 2036). 2010 ESC Congress 2010.
-
(2010)
2010 ESC Congress
-
-
Rao, S.V.1
-
69
-
-
0023942501
-
Diadenosine 5',5'''-p1,p4-tetraphosphate, a potential antithrombotic agent
-
Louie S., Kim B.K., Zamecnik P. Diadenosine 5',5'''-p1,p4-tetraphosphate, a potential antithrombotic agent. Thromb Res 1988, 49:557-565.
-
(1988)
Thromb Res
, vol.49
, pp. 557-565
-
-
Louie, S.1
Kim, B.K.2
Zamecnik, P.3
-
70
-
-
0026452776
-
Antithrombotic effect of beta,beta'-monochloromethylene diadenosine 5',5"'-p1,p4-tetraphosphate
-
Kim B.K., Zamecnik P., Taylor G., Guo M.J., Blackburn G.M. Antithrombotic effect of beta,beta'-monochloromethylene diadenosine 5',5"'-p1,p4-tetraphosphate. Proc Natl Acad Sci USA 1992, 89:11056-11058.
-
(1992)
Proc Natl Acad Sci USA
, vol.89
, pp. 11056-11058
-
-
Kim, B.K.1
Zamecnik, P.2
Taylor, G.3
Guo, M.J.4
Blackburn, G.M.5
-
71
-
-
0036121594
-
Elucidation of the thromboregulatory role of CD39/ectoapyrase in the ischemic brain
-
Pinsky D.J., Broekman M.J., Peschon J.J., Stocking K.L., Fujita T., Ramasamy R., et al. Elucidation of the thromboregulatory role of CD39/ectoapyrase in the ischemic brain. J Clin Invest 2002, 109:1031-1040.
-
(2002)
J Clin Invest
, vol.109
, pp. 1031-1040
-
-
Pinsky, D.J.1
Broekman, M.J.2
Peschon, J.J.3
Stocking, K.L.4
Fujita, T.5
Ramasamy, R.6
-
72
-
-
0345540629
-
Targeted disruption of CD39/ATP diphosphohydrolase results in disordered hemostasis and thromboregulation
-
Enjyoji K., Sevigny J., Lin Y., Frenette P.S., Christie P.D., Esch J.S., et al. Targeted disruption of CD39/ATP diphosphohydrolase results in disordered hemostasis and thromboregulation. Nat Med 1999, 5:1010-1017.
-
(1999)
Nat Med
, vol.5
, pp. 1010-1017
-
-
Enjyoji, K.1
Sevigny, J.2
Lin, Y.3
Frenette, P.S.4
Christie, P.D.5
Esch, J.S.6
-
73
-
-
79952116591
-
Identification of a tsetse fly salivary protein with dual inhibitory action on human platelet aggregation
-
Caljon G., De Ridder K., De Baetselier P., Coosemans M., Van Den Abbeele J. Identification of a tsetse fly salivary protein with dual inhibitory action on human platelet aggregation. PLoS One 2010, 5:e9671.
-
(2010)
PLoS One
, vol.5
-
-
Caljon, G.1
De Ridder, K.2
De Baetselier, P.3
Coosemans, M.4
Van Den Abbeele, J.5
-
74
-
-
1542269076
-
Structure and protein design of a human platelet function inhibitor
-
Dai J., Liu J., Deng Y., Smith T.M., Lu M. Structure and protein design of a human platelet function inhibitor. Cell 2004, 116:649-659.
-
(2004)
Cell
, vol.116
, pp. 649-659
-
-
Dai, J.1
Liu, J.2
Deng, Y.3
Smith, T.M.4
Lu, M.5
-
75
-
-
0027958181
-
Dose effects of aspirin on gastric prostaglandins and stomach mucosal injury
-
Lee M., Cryer B., Feldman M. Dose effects of aspirin on gastric prostaglandins and stomach mucosal injury. Ann Intern Med 1994, 120:184-189.
-
(1994)
Ann Intern Med
, vol.120
, pp. 184-189
-
-
Lee, M.1
Cryer, B.2
Feldman, M.3
-
76
-
-
65249135856
-
Antithrombotic therapy in heart failure: watchful wondering
-
Konstam M.A. Antithrombotic therapy in heart failure: watchful wondering. Circulation 2009, 119:1559-1561.
-
(2009)
Circulation
, vol.119
, pp. 1559-1561
-
-
Konstam, M.A.1
-
77
-
-
65949110335
-
Tp receptor antagonism: a new concept in atherothrombosis and stroke prevention
-
Chamorro A. Tp receptor antagonism: a new concept in atherothrombosis and stroke prevention. Cerebrovasc Dis 2009, 27(Suppl. 3):20-27.
-
(2009)
Cerebrovasc Dis
, vol.27
, Issue.SUPPL. 3
, pp. 20-27
-
-
Chamorro, A.1
-
78
-
-
25444465119
-
Atherosclerosis regression and TP receptor inhibition: effect of S18886 on plaque size and composition-a magnetic resonance imaging study
-
Viles-Gonzalez J.F., Fuster V., Corti R., Valdiviezo C., Hutter R., Corda S., et al. Atherosclerosis regression and TP receptor inhibition: effect of S18886 on plaque size and composition-a magnetic resonance imaging study. Eur Heart J 2005, 26:1557-1561.
-
(2005)
Eur Heart J
, vol.26
, pp. 1557-1561
-
-
Viles-Gonzalez, J.F.1
Fuster, V.2
Corti, R.3
Valdiviezo, C.4
Hutter, R.5
Corda, S.6
-
79
-
-
79958770159
-
Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): a randomised, double-blind, parallel-group trial
-
Bousser M.G., Amarenco P., Chamorro A., Fisher M., Ford I., Fox K.M., et al. Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): a randomised, double-blind, parallel-group trial. Lancet 2011, 377:2013-2022.
-
(2011)
Lancet
, vol.377
, pp. 2013-2022
-
-
Bousser, M.G.1
Amarenco, P.2
Chamorro, A.3
Fisher, M.4
Ford, I.5
Fox, K.M.6
-
80
-
-
79958765190
-
Vascular events after stroke: terutroban fails to perform
-
Lee M., Ovbiagele B. Vascular events after stroke: terutroban fails to perform. Lancet 2011, 377:1980-1982.
-
(2011)
Lancet
, vol.377
, pp. 1980-1982
-
-
Lee, M.1
Ovbiagele, B.2
-
81
-
-
33845927424
-
2 receptor antagonist, on rabbit platelets and aortic smooth muscle
-
2 receptor antagonist, on rabbit platelets and aortic smooth muscle. Pharmacology 2007, 79:50-56.
-
(2007)
Pharmacology
, vol.79
, pp. 50-56
-
-
Yoshida, M.1
Sato, Y.2
Shimura, T.3
Ohkubo, S.4
Honma, S.5
Tanaka, T.6
-
82
-
-
0344737009
-
The thromboxane receptor antagonist PBT-3, a hepoxilin stable analog, selectively antagonizes the TPalpha isoform in transfected cos-7 cells
-
Qiao N., Reynaud D., Demin P., Halushka P.V., Pace-Asciak C.R. The thromboxane receptor antagonist PBT-3, a hepoxilin stable analog, selectively antagonizes the TPalpha isoform in transfected cos-7 cells. J Pharmacol Exp Ther 2003, 307:1142-1147.
-
(2003)
J Pharmacol Exp Ther
, vol.307
, pp. 1142-1147
-
-
Qiao, N.1
Reynaud, D.2
Demin, P.3
Halushka, P.V.4
Pace-Asciak, C.R.5
-
83
-
-
0025203077
-
Cardioprotective actions of the specific thromboxane receptor antagonist (+)-s145na following coronary occlusion and reperfusion in the rat
-
Tsao P.S., Lefer A.M. Cardioprotective actions of the specific thromboxane receptor antagonist (+)-s145na following coronary occlusion and reperfusion in the rat. Res Commun Chem Pathol Pharmacol 1990, 70:205-211.
-
(1990)
Res Commun Chem Pathol Pharmacol
, vol.70
, pp. 205-211
-
-
Tsao, P.S.1
Lefer, A.M.2
-
84
-
-
0042386436
-
Effects of selective cyclooxygenase inhibitors on ischemia/reperfusion-induced hepatic microcirculatory dysfunction in mice
-
Ito Y., Katagiri H., Ishii K., Kakita A., Hayashi I., Majima M. Effects of selective cyclooxygenase inhibitors on ischemia/reperfusion-induced hepatic microcirculatory dysfunction in mice. Eur Surg Res 2003, 35:408-416.
-
(2003)
Eur Surg Res
, vol.35
, pp. 408-416
-
-
Ito, Y.1
Katagiri, H.2
Ishii, K.3
Kakita, A.4
Hayashi, I.5
Majima, M.6
-
85
-
-
0005556702
-
Augmented contraction of the human isolated coronary artery by sumatriptan: a possible role for endogenous thromboxane
-
Maassen VanDenBrink A., Bax W.A., Ferrari M.D., Zijlstra F.J., Bos E., Saxena P.R. Augmented contraction of the human isolated coronary artery by sumatriptan: a possible role for endogenous thromboxane. Br J Pharmacol 1996, 119:855-862.
-
(1996)
Br J Pharmacol
, vol.119
, pp. 855-862
-
-
Maassen VanDenBrink, A.1
Bax, W.A.2
Ferrari, M.D.3
Zijlstra, F.J.4
Bos, E.5
Saxena, P.R.6
-
86
-
-
0030611110
-
Thromboxane a2 receptor density increases during chronic exposure to thromboxane a2 receptor antagonists after porcine carotid bypass
-
Brothers T.E., Robison J.G., Elliott B.M., Boggs J.M., Halushka P.V. Thromboxane a2 receptor density increases during chronic exposure to thromboxane a2 receptor antagonists after porcine carotid bypass. Cardiovasc Surg 1997, 5:92-98.
-
(1997)
Cardiovasc Surg
, vol.5
, pp. 92-98
-
-
Brothers, T.E.1
Robison, J.G.2
Elliott, B.M.3
Boggs, J.M.4
Halushka, P.V.5
-
89
-
-
0028140168
-
2/prostaglandin endoperoxide receptor antagonist, versus aspirin as adjunct to thrombolysis in patients with acute myocardial infarction. The Ridogrel versus Aspirin Patency Trial (RAPT)
-
2/prostaglandin endoperoxide receptor antagonist, versus aspirin as adjunct to thrombolysis in patients with acute myocardial infarction. The Ridogrel versus Aspirin Patency Trial (RAPT). Circulation 1994, 89:588-595.
-
(1994)
Circulation
, vol.89
, pp. 588-595
-
-
The RAPT Investigators1
-
90
-
-
20244386797
-
Effects of the thromboxane synthetase inhibitor and receptor antagonist terbogrel in patients with primary pulmonary hypertension
-
Langleben D., Christman B.W., Barst R.J., Dias V.C., Galie N., Higenbottam T.W., et al. Effects of the thromboxane synthetase inhibitor and receptor antagonist terbogrel in patients with primary pulmonary hypertension. Am Heart J 2002, 143:E4.
-
(2002)
Am Heart J
, vol.143
-
-
Langleben, D.1
Christman, B.W.2
Barst, R.J.3
Dias, V.C.4
Galie, N.5
Higenbottam, T.W.6
-
91
-
-
3142512628
-
2 receptor and synthase inhibitor, in healthy subjects
-
2 receptor and synthase inhibitor, in healthy subjects. Br J Clin Pharmacol 2004, 58:40-51.
-
(2004)
Br J Clin Pharmacol
, vol.58
, pp. 40-51
-
-
Guth, B.D.1
Narjes, H.2
Schubert, H.D.3
Tanswell, P.4
Riedel, A.5
Nehmiz, G.6
-
92
-
-
0027198798
-
Effect of picotamide on the clinical progression of peripheral vascular disease. A double-blind placebo-controlled study. The ADEP group
-
Balsano F., Violi F. Effect of picotamide on the clinical progression of peripheral vascular disease. A double-blind placebo-controlled study. The ADEP group. Circulation 1993, 87:1563-1569.
-
(1993)
Circulation
, vol.87
, pp. 1563-1569
-
-
Balsano, F.1
Violi, F.2
-
93
-
-
34249856927
-
A review of picotamide in the reduction of cardiovascular events in diabetic patients
-
Celestini A., Violi F. A review of picotamide in the reduction of cardiovascular events in diabetic patients. Vasc Health Risk Manag 2007, 3:93-98.
-
(2007)
Vasc Health Risk Manag
, vol.3
, pp. 93-98
-
-
Celestini, A.1
Violi, F.2
-
94
-
-
4944241267
-
2 synthase and receptor, reduces 2-year mortality in diabetics with peripheral arterial disease: the DAVID study
-
2 synthase and receptor, reduces 2-year mortality in diabetics with peripheral arterial disease: the DAVID study. Eur Heart J 2004, 25:1845-1852.
-
(2004)
Eur Heart J
, vol.25
, pp. 1845-1852
-
-
Neri Serneri, G.G.1
Coccheri, S.2
Marubini, E.3
Violi, F.4
-
95
-
-
0032951722
-
In vivo antithrombotic effects of a nitric oxide-releasing aspirin derivative, ncx-4016
-
Wallace J.L., Muscara M.N., McKnight W., Dicay M., Del Soldato P., Cirino G. In vivo antithrombotic effects of a nitric oxide-releasing aspirin derivative, ncx-4016. Thromb Res 1999, 93:43-50.
-
(1999)
Thromb Res
, vol.93
, pp. 43-50
-
-
Wallace, J.L.1
Muscara, M.N.2
McKnight, W.3
Dicay, M.4
Del Soldato, P.5
Cirino, G.6
-
96
-
-
15444374171
-
Nitroaspirin plus clopidogrel versus aspirin plus clopidogrel against platelet thromboembolism and intimal thickening in mice
-
Momi S., Pitchford S.C., Alberti P.F., Minuz P., Del Soldato P., Gresele P. Nitroaspirin plus clopidogrel versus aspirin plus clopidogrel against platelet thromboembolism and intimal thickening in mice. Thromb Haemost 2005, 93:535-543.
-
(2005)
Thromb Haemost
, vol.93
, pp. 535-543
-
-
Momi, S.1
Pitchford, S.C.2
Alberti, P.F.3
Minuz, P.4
Del Soldato, P.5
Gresele, P.6
-
97
-
-
0035956891
-
Effects of nitric oxide-releasing aspirin versus aspirin on restenosis in hypercholesterolemic mice
-
Napoli C., Cirino G., Del Soldato P., Sorrentino R., Sica V., Condorelli M., et al. Effects of nitric oxide-releasing aspirin versus aspirin on restenosis in hypercholesterolemic mice. Proc Natl Acad Sci U S A 2001, 98:2860-2864.
-
(2001)
Proc Natl Acad Sci U S A
, vol.98
, pp. 2860-2864
-
-
Napoli, C.1
Cirino, G.2
Del Soldato, P.3
Sorrentino, R.4
Sica, V.5
Condorelli, M.6
-
98
-
-
34247121053
-
Functional effects of nitric oxide-releasing aspirin on vein conduits of diabetic patients undergoing CABG
-
Lorusso R., De Cicco G., Beghi C., Gherli T., Poli E., Corradi D., et al. Functional effects of nitric oxide-releasing aspirin on vein conduits of diabetic patients undergoing CABG. Int J Cardiol 2007, 118:164-169.
-
(2007)
Int J Cardiol
, vol.118
, pp. 164-169
-
-
Lorusso, R.1
De Cicco, G.2
Beghi, C.3
Gherli, T.4
Poli, E.5
Corradi, D.6
-
99
-
-
0037373349
-
Gastrointestinal safety of no-aspirin (NCX-4016) in healthy human volunteers: a proof of concept endoscopic study
-
Fiorucci S., Santucci L., Gresele P., Faccino R.M., Del Soldato P., Morelli A. Gastrointestinal safety of no-aspirin (NCX-4016) in healthy human volunteers: a proof of concept endoscopic study. Gastroenterology 2003, 124:600-607.
-
(2003)
Gastroenterology
, vol.124
, pp. 600-607
-
-
Fiorucci, S.1
Santucci, L.2
Gresele, P.3
Faccino, R.M.4
Del Soldato, P.5
Morelli, A.6
-
100
-
-
0035895332
-
Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials
-
Chew D.P., Bhatt D.L., Sapp S., Topol E.J. Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials. Circulation 2001, 103:201-206.
-
(2001)
Circulation
, vol.103
, pp. 201-206
-
-
Chew, D.P.1
Bhatt, D.L.2
Sapp, S.3
Topol, E.J.4
-
101
-
-
0003215841
-
GPIIb-IIIa antagonists demonstrate a dose-dependent inhibition and potentiation of soluble CD40L (CD154) release during platelet stimulation
-
II-318.
-
Nannizzi-Alaimo N., Alves V.L., Prasad S., et al. GPIIb-IIIa antagonists demonstrate a dose-dependent inhibition and potentiation of soluble CD40L (CD154) release during platelet stimulation. Circulation 2001, 104. II-318.
-
(2001)
Circulation
, vol.104
-
-
Nannizzi-Alaimo, N.1
Alves, V.L.2
Prasad, S.3
-
102
-
-
0034332785
-
Evidence of platelet activation during treatment with a GPIIb/IIIa antagonist in patients presenting with acute coronary syndromes
-
Cox D., Smith R., Quinn M., Theroux P., Crean P., Fitzgerald D.J. Evidence of platelet activation during treatment with a GPIIb/IIIa antagonist in patients presenting with acute coronary syndromes. J Am Coll Cardiol 2000, 36:1514-1519.
-
(2000)
J Am Coll Cardiol
, vol.36
, pp. 1514-1519
-
-
Cox, D.1
Smith, R.2
Quinn, M.3
Theroux, P.4
Crean, P.5
Fitzgerald, D.J.6
-
103
-
-
0033674866
-
Platelet-leukocyte cross talk in whole blood
-
Li N., Hu H., Lindqvist M., Wikstrom-Jonsson E., Goodall A.H., Hjemdahl P. Platelet-leukocyte cross talk in whole blood. Arterioscler Thromb Vasc Biol 2000, 20:2702-2708.
-
(2000)
Arterioscler Thromb Vasc Biol
, vol.20
, pp. 2702-2708
-
-
Li, N.1
Hu, H.2
Lindqvist, M.3
Wikstrom-Jonsson, E.4
Goodall, A.H.5
Hjemdahl, P.6
-
104
-
-
0037118664
-
Platelet glycoprotein IIb/IIIa inhibitors: Recognition of a two-edged sword?
-
Quinn M.J., Plow E.F., Topol E.J. Platelet glycoprotein IIb/IIIa inhibitors: Recognition of a two-edged sword?. Circulation 2002, 106:379-385.
-
(2002)
Circulation
, vol.106
, pp. 379-385
-
-
Quinn, M.J.1
Plow, E.F.2
Topol, E.J.3
-
105
-
-
0035028123
-
Occupancy of the internal and external pools of glycoprotein IIb/IIIa following abciximab bolus and infusion
-
Quinn M.J., Murphy R.T., Dooley M., Foley J.B., Fitzgerald D.J. Occupancy of the internal and external pools of glycoprotein IIb/IIIa following abciximab bolus and infusion. J Pharmacol Exp Ther 2001, 297:496-500.
-
(2001)
J Pharmacol Exp Ther
, vol.297
, pp. 496-500
-
-
Quinn, M.J.1
Murphy, R.T.2
Dooley, M.3
Foley, J.B.4
Fitzgerald, D.J.5
-
106
-
-
38949130475
-
Application of high-throughput screening to identify a novel alphaIIb-specific small-molecule inhibitor of alphaIIbbeta3-mediated platelet interaction with fibrinogen
-
Blue R., Murcia M., Karan C., Jirouskova M., Coller B.S. Application of high-throughput screening to identify a novel alphaIIb-specific small-molecule inhibitor of alphaIIbbeta3-mediated platelet interaction with fibrinogen. Blood 2008, 111:1248-1256.
-
(2008)
Blood
, vol.111
, pp. 1248-1256
-
-
Blue, R.1
Murcia, M.2
Karan, C.3
Jirouskova, M.4
Coller, B.S.5
-
107
-
-
67651068728
-
Structural and therapeutic insights from the species specificity and in vivo antithrombotic activity of a novel alphaIIb-specific alphaIIbbeta3 antagonist
-
Blue R., Kowalska M.A., Hirsch J., Murcia M., Janczak C.A., Harrington A., et al. Structural and therapeutic insights from the species specificity and in vivo antithrombotic activity of a novel alphaIIb-specific alphaIIbbeta3 antagonist. Blood 2009, 114:195-201.
-
(2009)
Blood
, vol.114
, pp. 195-201
-
-
Blue, R.1
Kowalska, M.A.2
Hirsch, J.3
Murcia, M.4
Janczak, C.A.5
Harrington, A.6
-
108
-
-
78649747986
-
Closed headpiece of integrin alphaIIbbeta3 and its complex with an alphaIIbbeta3-specific antagonist that does not induce opening
-
Zhu J., Negri A., Provasi D., Filizola M., Coller B.S., Springer T.A. Closed headpiece of integrin alphaIIbbeta3 and its complex with an alphaIIbbeta3-specific antagonist that does not induce opening. Blood 2010, 116:5050-5059.
-
(2010)
Blood
, vol.116
, pp. 5050-5059
-
-
Zhu, J.1
Negri, A.2
Provasi, D.3
Filizola, M.4
Coller, B.S.5
Springer, T.A.6
-
109
-
-
61849180442
-
Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study
-
Becker R.C., Moliterno D.J., Jennings L.K., Pieper K.S., Pei J., Niederman A., et al. Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study. Lancet 2009, 373:919-928.
-
(2009)
Lancet
, vol.373
, pp. 919-928
-
-
Becker, R.C.1
Moliterno, D.J.2
Jennings, L.K.3
Pieper, K.S.4
Pei, J.5
Niederman, A.6
-
110
-
-
33645858005
-
Agonists and antagonists of protease activated receptors (PARs)
-
Barry G.D., Le G.T., Fairlie D.P. Agonists and antagonists of protease activated receptors (PARs). Curr Med Chem 2006, 13:243-265.
-
(2006)
Curr Med Chem
, vol.13
, pp. 243-265
-
-
Barry, G.D.1
Le, G.T.2
Fairlie, D.P.3
-
111
-
-
0033559805
-
Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin
-
Kahn M.L., Nakanishi-Matsui M., Shapiro M.J., Ishihara H., Coughlin S.R. Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin. J Clin Invest 1999, 103:879-887.
-
(1999)
J Clin Invest
, vol.103
, pp. 879-887
-
-
Kahn, M.L.1
Nakanishi-Matsui, M.2
Shapiro, M.J.3
Ishihara, H.4
Coughlin, S.R.5
-
112
-
-
0034967927
-
Administration of a potent antagonist of protease-activated receptor-1 (PAR-1) attenuates vascular restenosis following balloon angioplasty in rats
-
Andrade-Gordon P., Derian C.K., Maryanoff B.E., Zhang H.C., Addo M.F., Cheung W., et al. Administration of a potent antagonist of protease-activated receptor-1 (PAR-1) attenuates vascular restenosis following balloon angioplasty in rats. J Pharmacol Exp Ther 2001, 298:34-42.
-
(2001)
J Pharmacol Exp Ther
, vol.298
, pp. 34-42
-
-
Andrade-Gordon, P.1
Derian, C.K.2
Maryanoff, B.E.3
Zhang, H.C.4
Addo, M.F.5
Cheung, W.6
-
113
-
-
76549094772
-
Pharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular diseases
-
Siller-Matula J.M., Krumphuber J., Jilma B. Pharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular diseases. Br J Pharmacol 2010, 159:502-517.
-
(2010)
Br J Pharmacol
, vol.159
, pp. 502-517
-
-
Siller-Matula, J.M.1
Krumphuber, J.2
Jilma, B.3
-
114
-
-
85027946204
-
Safety and tolerability of atopaxar in the treatment of patients with acute coronary syndromes: the lessons from antagonizing the cellular effects of thrombin-acute coronary syndromes trial
-
O'Donoghue M.L., Bhatt D.L., Wiviott S.D., Goodman S.G., Fitzgerald D.J., Angiolillo D.J., et al. Safety and tolerability of atopaxar in the treatment of patients with acute coronary syndromes: the lessons from antagonizing the cellular effects of thrombin-acute coronary syndromes trial. Circulation 2011, 123:1843-1853.
-
(2011)
Circulation
, vol.123
, pp. 1843-1853
-
-
O'Donoghue, M.L.1
Bhatt, D.L.2
Wiviott, S.D.3
Goodman, S.G.4
Fitzgerald, D.J.5
Angiolillo, D.J.6
-
115
-
-
84882645953
-
-
US NIH Cg. Trial to assess the effects of SCH 530348 in preventing heart attack and stroke in patients with acute coronary syndrome (TRACER) 2011.
-
US NIH Cg. Trial to assess the effects of SCH 530348 in preventing heart attack and stroke in patients with acute coronary syndrome (TRACER) 2011.
-
-
-
-
116
-
-
84882577111
-
-
US NIH Cg. Trial to assess the effects of SCH 530348 in preventing heart attack and stroke in patients with atherosclerosis (TRA2P TIMI-50). 2010.
-
US NIH Cg. Trial to assess the effects of SCH 530348 in preventing heart attack and stroke in patients with atherosclerosis (TRA2P TIMI-50). 2010.
-
-
-
-
117
-
-
85027951718
-
Randomized trial of atopaxar in the treatment of patients with coronary artery disease: the lessons from antagonizing the cellular effect of thrombin-coronary artery disease trial
-
Wiviott S.D., Flather M.D., O'Donoghue M.L., Goto S., Fitzgerald D.J., Cura F., et al. Randomized trial of atopaxar in the treatment of patients with coronary artery disease: the lessons from antagonizing the cellular effect of thrombin-coronary artery disease trial. Circulation 2011, 123:1854-1863.
-
(2011)
Circulation
, vol.123
, pp. 1854-1863
-
-
Wiviott, S.D.1
Flather, M.D.2
O'Donoghue, M.L.3
Goto, S.4
Fitzgerald, D.J.5
Cura, F.6
-
118
-
-
0036797590
-
Pepducin-based intervention of thrombin-receptor signaling and systemic platelet activation
-
Covic L., Misra M., Badar J., Singh C., Kuliopulos A. Pepducin-based intervention of thrombin-receptor signaling and systemic platelet activation. Nat Med 2002, 8:1161-1165.
-
(2002)
Nat Med
, vol.8
, pp. 1161-1165
-
-
Covic, L.1
Misra, M.2
Badar, J.3
Singh, C.4
Kuliopulos, A.5
-
119
-
-
34247402058
-
Targeting ligand-induced binding sites on GPIIb/IIIa via single-chain antibody allows effective anticoagulation without bleeding time prolongation
-
Stoll P., Bassler N., Hagemeyer C.E., Eisenhardt S.U., Chen Y.C., Schmidt R., et al. Targeting ligand-induced binding sites on GPIIb/IIIa via single-chain antibody allows effective anticoagulation without bleeding time prolongation. Arterioscler Thromb Vasc Biol 2007, 27:1206-1212.
-
(2007)
Arterioscler Thromb Vasc Biol
, vol.27
, pp. 1206-1212
-
-
Stoll, P.1
Bassler, N.2
Hagemeyer, C.E.3
Eisenhardt, S.U.4
Chen, Y.C.5
Schmidt, R.6
-
120
-
-
0036162199
-
Inhibition of platelet glycoprotein Ib, glycoprotein IIb/IIIa, or both by monoclonal antibodies prevents arterial thrombosis in baboons
-
Wu D., Meiring M., Kotze H.F., Deckmyn H., Cauwenberghs N. Inhibition of platelet glycoprotein Ib, glycoprotein IIb/IIIa, or both by monoclonal antibodies prevents arterial thrombosis in baboons. Arterioscler Thromb Vasc Biol 2002, 22:323-328.
-
(2002)
Arterioscler Thromb Vasc Biol
, vol.22
, pp. 323-328
-
-
Wu, D.1
Meiring, M.2
Kotze, H.F.3
Deckmyn, H.4
Cauwenberghs, N.5
-
121
-
-
0028361191
-
Relative antithrombotic effects of monoclonal antibodies targeting different platelet glycoprotein-adhesive molecule interactions in nonhuman primates
-
Cadroy Y., Hanson S.R., Kelly A.B., Marzec U.M., Evatt B.L., Kunicki T.J., et al. Relative antithrombotic effects of monoclonal antibodies targeting different platelet glycoprotein-adhesive molecule interactions in nonhuman primates. Blood 1994, 83:3218-3224.
-
(1994)
Blood
, vol.83
, pp. 3218-3224
-
-
Cadroy, Y.1
Hanson, S.R.2
Kelly, A.B.3
Marzec, U.M.4
Evatt, B.L.5
Kunicki, T.J.6
-
122
-
-
0036917764
-
Pathogenic effects of anti-glycoprotein Ib antibodies on megakaryocytes and platelets
-
Alimardani G., Guichard J., Fichelson S., Cramer E.M. Pathogenic effects of anti-glycoprotein Ib antibodies on megakaryocytes and platelets. Thromb Haemost 2002, 88:1039-1046.
-
(2002)
Thromb Haemost
, vol.88
, pp. 1039-1046
-
-
Alimardani, G.1
Guichard, J.2
Fichelson, S.3
Cramer, E.M.4
-
123
-
-
54949095069
-
The humanized anti-glycoprotein Ib monoclonal antibody h6b4-Fab is a potent and safe antithrombotic in a high shear arterial thrombosis model in baboons
-
Fontayne A., Meiring M., Lamprecht S., Roodt J., Demarsin E., Barbeaux P., et al. The humanized anti-glycoprotein Ib monoclonal antibody h6b4-Fab is a potent and safe antithrombotic in a high shear arterial thrombosis model in baboons. Thromb Haemost 2008, 100:670-677.
-
(2008)
Thromb Haemost
, vol.100
, pp. 670-677
-
-
Fontayne, A.1
Meiring, M.2
Lamprecht, S.3
Roodt, J.4
Demarsin, E.5
Barbeaux, P.6
-
124
-
-
0032031490
-
Antithrombotic effect of crotalin, a platelet membrane glycoprotein Ib antagonist from venom of crotalus atrox
-
Chang M.C., Lin H.K., Peng H.C., Huang T.F. Antithrombotic effect of crotalin, a platelet membrane glycoprotein Ib antagonist from venom of crotalus atrox. Blood 1998, 91:1582-1589.
-
(1998)
Blood
, vol.91
, pp. 1582-1589
-
-
Chang, M.C.1
Lin, H.K.2
Peng, H.C.3
Huang, T.F.4
-
125
-
-
0031805437
-
The CDNA cloning and molecular characterization of a snake venom platelet glycoprotein Ib-binding protein, mamushigin, from agkistrodon halys blomhoffii venom
-
Sakurai Y., Fujimura Y., Kokubo T., Imamura K., Kawasaki T., Handa M., et al. The CDNA cloning and molecular characterization of a snake venom platelet glycoprotein Ib-binding protein, mamushigin, from agkistrodon halys blomhoffii venom. Thromb Haemost 1998, 79:1199-1207.
-
(1998)
Thromb Haemost
, vol.79
, pp. 1199-1207
-
-
Sakurai, Y.1
Fujimura, Y.2
Kokubo, T.3
Imamura, K.4
Kawasaki, T.5
Handa, M.6
-
126
-
-
0028804347
-
Antithrombotic effect of a recombinant von Willebrand factor, VCL, on nitrogen laser-induced thrombus formation in guinea pig mesenteric arteries
-
Azzam K., Garfinkel L.I., Bal dit Sollier C., Cisse Thiam M., Drouet L. Antithrombotic effect of a recombinant von Willebrand factor, VCL, on nitrogen laser-induced thrombus formation in guinea pig mesenteric arteries. Thromb Haemost 1995, 73:318-323.
-
(1995)
Thromb Haemost
, vol.73
, pp. 318-323
-
-
Azzam, K.1
Garfinkel, L.I.2
Bal dit Sollier, C.3
Cisse Thiam, M.4
Drouet, L.5
-
127
-
-
0028641293
-
Abolition of cyclic flow variations in stenosed, endothelium-injured coronary arteries in nonhuman primates with a peptide fragment (VCL) derived from human plasma von Willebrand factor-glycoprotein Ib binding domain
-
McGhie A.I., McNatt J., Ezov N., Cui K., Mower L.K., Hagay Y., et al. Abolition of cyclic flow variations in stenosed, endothelium-injured coronary arteries in nonhuman primates with a peptide fragment (VCL) derived from human plasma von Willebrand factor-glycoprotein Ib binding domain. Circulation 1994, 90:2976-2981.
-
(1994)
Circulation
, vol.90
, pp. 2976-2981
-
-
McGhie, A.I.1
McNatt, J.2
Ezov, N.3
Cui, K.4
Mower, L.K.5
Hagay, Y.6
-
128
-
-
0031974170
-
Antagonism of VWF inhibits both injury induced arterial and venous thrombosis in the hamster
-
Yamamoto H., Vreys I., Stassen J.M., Yoshimoto R., Vermylen J., Hoylaerts M.F. Antagonism of VWF inhibits both injury induced arterial and venous thrombosis in the hamster. Thromb Haemost 1998, 79:202-210.
-
(1998)
Thromb Haemost
, vol.79
, pp. 202-210
-
-
Yamamoto, H.1
Vreys, I.2
Stassen, J.M.3
Yoshimoto, R.4
Vermylen, J.5
Hoylaerts, M.F.6
-
129
-
-
0035279906
-
Anti-human VWF monoclonal antibody, AJVW-2 Fab, inhibits repetitive coronary artery thrombosis without bleeding time prolongation in dogs
-
Kageyama S., Yamamoto H., Nakazawa H., Yoshimoto R. Anti-human VWF monoclonal antibody, AJVW-2 Fab, inhibits repetitive coronary artery thrombosis without bleeding time prolongation in dogs. Thromb Res 2001, 101:395-404.
-
(2001)
Thromb Res
, vol.101
, pp. 395-404
-
-
Kageyama, S.1
Yamamoto, H.2
Nakazawa, H.3
Yoshimoto, R.4
-
130
-
-
0029917899
-
Aurin tricarboxylic acid inhibits adhesion of platelets to subendothelium
-
Owens M.R., Holme S. Aurin tricarboxylic acid inhibits adhesion of platelets to subendothelium. Thromb Res 1996, 81:177-185.
-
(1996)
Thromb Res
, vol.81
, pp. 177-185
-
-
Owens, M.R.1
Holme, S.2
-
131
-
-
0029123084
-
Aurintricarboxylic acid reduces platelet deposition in stenosed and endothelially injured rabbit carotid arteries more effectively than other antiplatelet interventions
-
Golino P., Ragni M., Cirillo P., Pascucci I., Ezekowitz M.D., Pawashe A., et al. Aurintricarboxylic acid reduces platelet deposition in stenosed and endothelially injured rabbit carotid arteries more effectively than other antiplatelet interventions. Thromb Haemost 1995, 74:974-979.
-
(1995)
Thromb Haemost
, vol.74
, pp. 974-979
-
-
Golino, P.1
Ragni, M.2
Cirillo, P.3
Pascucci, I.4
Ezekowitz, M.D.5
Pawashe, A.6
-
132
-
-
67650236718
-
ARC-1779, a pegylated aptamer antagonist of von Willebrand factor for potential use as an anticoagulant or antithrombotic agent
-
Cosmi B. ARC-1779, a pegylated aptamer antagonist of von Willebrand factor for potential use as an anticoagulant or antithrombotic agent. Curr Opin Mol Ther 2009, 11:322-328.
-
(2009)
Curr Opin Mol Ther
, vol.11
, pp. 322-328
-
-
Cosmi, B.1
-
134
-
-
79961210182
-
The von Willebrand inhibitor ARC1779 reduces cerebral embolization after carotid endarterectomy: a randomized trial
-
Markus H.S., McCollum C., Imray C., Goulder M.A., Gilbert J., King A. The von Willebrand inhibitor ARC1779 reduces cerebral embolization after carotid endarterectomy: a randomized trial. Stroke 2011, 42:2149-2153.
-
(2011)
Stroke
, vol.42
, pp. 2149-2153
-
-
Markus, H.S.1
McCollum, C.2
Imray, C.3
Goulder, M.A.4
Gilbert, J.5
King, A.6
-
135
-
-
37349040378
-
First-in-human evaluation of anti von Willebrand factor therapeutic aptamer arc1779 in healthy volunteers
-
Gilbert J.C., DeFeo-Fraulini T., Hutabarat R.M., Horvath C.J., Merlino P.G., Marsh H.N., et al. First-in-human evaluation of anti von Willebrand factor therapeutic aptamer arc1779 in healthy volunteers. Circulation 2007, 116:2678-2686.
-
(2007)
Circulation
, vol.116
, pp. 2678-2686
-
-
Gilbert, J.C.1
DeFeo-Fraulini, T.2
Hutabarat, R.M.3
Horvath, C.J.4
Merlino, P.G.5
Marsh, H.N.6
-
137
-
-
79960633933
-
Toxins in thrombosis and haemostasis: potential beyond imagination
-
Kini R.M. Toxins in thrombosis and haemostasis: potential beyond imagination. J Thromb Haemost 2011, 9(Suppl. 1):195-208.
-
(2011)
J Thromb Haemost
, vol.9
, Issue.SUPPL. 1
, pp. 195-208
-
-
Kini, R.M.1
-
138
-
-
49849103616
-
A snake venom metalloproteinase, kistomin, cleaves platelet glycoprotein VI and impairs platelet functions
-
Hsu C.C., Wu W.B., Huang T.F. A snake venom metalloproteinase, kistomin, cleaves platelet glycoprotein VI and impairs platelet functions. J Thromb Haemost 2008, 6:1578-1585.
-
(2008)
J Thromb Haemost
, vol.6
, pp. 1578-1585
-
-
Hsu, C.C.1
Wu, W.B.2
Huang, T.F.3
-
139
-
-
43049116482
-
A novel antiplatelet antibody therapy that induces camp-dependent endocytosis of the GPVI/Fc receptor gamma-chain complex
-
Takayama H., Hosaka Y., Nakayama K., Shirakawa K., Naitoh K., Matsusue T., et al. A novel antiplatelet antibody therapy that induces camp-dependent endocytosis of the GPVI/Fc receptor gamma-chain complex. J Clin Invest 2008, 118:1785-1795.
-
(2008)
J Clin Invest
, vol.118
, pp. 1785-1795
-
-
Takayama, H.1
Hosaka, Y.2
Nakayama, K.3
Shirakawa, K.4
Naitoh, K.5
Matsusue, T.6
-
140
-
-
58849165421
-
Small-molecule inhibitors of integrin alpha2beta1 that prevent pathological thrombus formation via an allosteric mechanism
-
Miller M.W., Basra S., Kulp D.W., Billings P.C., Choi S., Beavers M.P., et al. Small-molecule inhibitors of integrin alpha2beta1 that prevent pathological thrombus formation via an allosteric mechanism. Proc Natl Acad Sci U S A 2009, 106:719-724.
-
(2009)
Proc Natl Acad Sci U S A
, vol.106
, pp. 719-724
-
-
Miller, M.W.1
Basra, S.2
Kulp, D.W.3
Billings, P.C.4
Choi, S.5
Beavers, M.P.6
-
141
-
-
0034663794
-
Isolation and characterization of EMS16, a c-lectin type protein from echis multisquamatus venom, a potent and selective inhibitor of the alpha2beta1 integrin
-
Marcinkiewicz C., Lobb R.R., Marcinkiewicz M.M., Daniel J.L., Smith J.B., Dangelmaier C., et al. Isolation and characterization of EMS16, a c-lectin type protein from echis multisquamatus venom, a potent and selective inhibitor of the alpha2beta1 integrin. Biochemistry 2000, 39:9859-9867.
-
(2000)
Biochemistry
, vol.39
, pp. 9859-9867
-
-
Marcinkiewicz, C.1
Lobb, R.R.2
Marcinkiewicz, M.M.3
Daniel, J.L.4
Smith, J.B.5
Dangelmaier, C.6
-
142
-
-
30444437494
-
C1qTNF-related protein-1 (CTRP-1): a vascular wall protein that inhibits collagen-induced platelet aggregation by blocking VWF binding to collagen
-
Lasser G., Guchhait P., Ellsworth J.L., Sheppard P., Lewis K., Bishop P., et al. C1qTNF-related protein-1 (CTRP-1): a vascular wall protein that inhibits collagen-induced platelet aggregation by blocking VWF binding to collagen. Blood 2006, 107:423-430.
-
(2006)
Blood
, vol.107
, pp. 423-430
-
-
Lasser, G.1
Guchhait, P.2
Ellsworth, J.L.3
Sheppard, P.4
Lewis, K.5
Bishop, P.6
-
143
-
-
1442290149
-
Soluble glycoprotein VI dimer inhibits platelet adhesion and aggregation to the injured vessel wall in vivo
-
Massberg S., Konrad I., Bultmann A., Schulz C., Munch G., Peluso M., et al. Soluble glycoprotein VI dimer inhibits platelet adhesion and aggregation to the injured vessel wall in vivo. FASEB J 2004, 18:397-399.
-
(2004)
FASEB J
, vol.18
, pp. 397-399
-
-
Massberg, S.1
Konrad, I.2
Bultmann, A.3
Schulz, C.4
Munch, G.5
Peluso, M.6
-
144
-
-
85027958733
-
Novel antiplatelet drug revacept (dimeric glycoprotein VI-Fc) specifically and efficiently inhibited collagen-induced platelet aggregation without affecting general hemostasis in humans
-
Ungerer M., Rosport K., Bultmann A., Piechatzek R., Uhland K., Schlieper P., et al. Novel antiplatelet drug revacept (dimeric glycoprotein VI-Fc) specifically and efficiently inhibited collagen-induced platelet aggregation without affecting general hemostasis in humans. Circulation 2011, 123:1891-1899.
-
(2011)
Circulation
, vol.123
, pp. 1891-1899
-
-
Ungerer, M.1
Rosport, K.2
Bultmann, A.3
Piechatzek, R.4
Uhland, K.5
Schlieper, P.6
-
145
-
-
0033856462
-
PI3-kinase inhibition: A target for drug development?
-
Stein R.C., Waterfield M.D. PI3-kinase inhibition: A target for drug development?. Mol Med Today 2000, 6:347-357.
-
(2000)
Mol Med Today
, vol.6
, pp. 347-357
-
-
Stein, R.C.1
Waterfield, M.D.2
-
146
-
-
21044454703
-
PI 3-kinase p110beta: a new target for antithrombotic therapy
-
Jackson S.P., Schoenwaelder S.M., Goncalves I., Nesbitt W.S., Yap C.L., Wright C.E., et al. PI 3-kinase p110beta: a new target for antithrombotic therapy. Nat Med 2005, 11:507-514.
-
(2005)
Nat Med
, vol.11
, pp. 507-514
-
-
Jackson, S.P.1
Schoenwaelder, S.M.2
Goncalves, I.3
Nesbitt, W.S.4
Yap, C.L.5
Wright, C.E.6
-
147
-
-
70349338807
-
Apd791, 3-methoxy-n-(3-(1-methyl-1h-pyrazol-5-yl)-4-(2-morpholinoethoxy)phenyl)b en zamide, a novel 5-hydroxytryptamine 2A receptor antagonist: pharmacological profile, pharmacokinetics, platelet activity and vascular biology
-
Adams J.W., Ramirez J., Shi Y., Thomsen W., Frazer J., Morgan M., et al. Apd791, 3-methoxy-n-(3-(1-methyl-1h-pyrazol-5-yl)-4-(2-morpholinoethoxy)phenyl)b en zamide, a novel 5-hydroxytryptamine 2A receptor antagonist: pharmacological profile, pharmacokinetics, platelet activity and vascular biology. J Pharmacol Exp Ther 2009, 331:96-103.
-
(2009)
J Pharmacol Exp Ther
, vol.331
, pp. 96-103
-
-
Adams, J.W.1
Ramirez, J.2
Shi, Y.3
Thomsen, W.4
Frazer, J.5
Morgan, M.6
-
149
-
-
46249118961
-
Sarpogrelate-aspirin comparative clinical study for efficacy and safety in secondary prevention of cerebral infarction (S-ACCESS): a randomized, double-blind, aspirin-controlled trial
-
Shinohara Y., Nishimaru K., Sawada T., Terashi A., Handa S., Hirai S., et al. Sarpogrelate-aspirin comparative clinical study for efficacy and safety in secondary prevention of cerebral infarction (S-ACCESS): a randomized, double-blind, aspirin-controlled trial. Stroke 2008, 39:1827-1833.
-
(2008)
Stroke
, vol.39
, pp. 1827-1833
-
-
Shinohara, Y.1
Nishimaru, K.2
Sawada, T.3
Terashi, A.4
Handa, S.5
Hirai, S.6
-
150
-
-
0038556688
-
2A antagonist, retards the progression of atherosclerosis through a novel mechanism
-
2A antagonist, retards the progression of atherosclerosis through a novel mechanism. Atherosclerosis 2003, 168:23-31.
-
(2003)
Atherosclerosis
, vol.168
, pp. 23-31
-
-
Hayashi, T.1
Sumi, D.2
Matsui-Hirai, H.3
Fukatsu, A.4
Arockia Rani, P.J.5
Kano, H.6
-
151
-
-
0038545749
-
Sarpogrelate treatment reduces restenosis after coronary stenting
-
Fujita M., Mizuno K., Ho M., Tsukahara R., Miyamoto A., Miki O., et al. Sarpogrelate treatment reduces restenosis after coronary stenting. Am Heart J 2003, 145:E16.
-
(2003)
Am Heart J
, vol.145
-
-
Fujita, M.1
Mizuno, K.2
Ho, M.3
Tsukahara, R.4
Miyamoto, A.5
Miki, O.6
-
153
-
-
84882587534
-
-
US NIH Cg. Single-dose safety study of APD791 in healthy volunteers. 2008.
-
US NIH Cg. Single-dose safety study of APD791 in healthy volunteers. 2008.
-
-
-
-
154
-
-
24144449528
-
Association between prostaglandin E receptor subtype EP4 overexpression and unstable phenotype in atherosclerotic plaques in human
-
Cipollone F., Fazia M.L., Iezzi A., Cuccurullo C., De Cesare D., Ucchino S., et al. Association between prostaglandin E receptor subtype EP4 overexpression and unstable phenotype in atherosclerotic plaques in human. Arterioscler Thromb Vasc Biol 2005, 25:1925-1931.
-
(2005)
Arterioscler Thromb Vasc Biol
, vol.25
, pp. 1925-1931
-
-
Cipollone, F.1
Fazia, M.L.2
Iezzi, A.3
Cuccurullo, C.4
De Cesare, D.5
Ucchino, S.6
-
156
-
-
74849116661
-
3 receptor antagonist, as a novel antiplatelet agent that does not prolong bleeding
-
3 receptor antagonist, as a novel antiplatelet agent that does not prolong bleeding. J Med Chem 2010, 53:18-36.
-
(2010)
J Med Chem
, vol.53
, pp. 18-36
-
-
Singh, J.1
Zeller, W.2
Zhou, N.3
Hategan, G.4
Mishra, R.K.5
Polozov, A.6
-
157
-
-
85047694191
-
Role of Gas6 receptors in platelet signaling during thrombus stabilization and implications for antithrombotic therapy
-
Angelillo-Scherrer A., Burnier L., Flores N., Savi P., DeMol M., Schaeffer P., et al. Role of Gas6 receptors in platelet signaling during thrombus stabilization and implications for antithrombotic therapy. J Clin Invest 2005, 115:237-246.
-
(2005)
J Clin Invest
, vol.115
, pp. 237-246
-
-
Angelillo-Scherrer, A.1
Burnier, L.2
Flores, N.3
Savi, P.4
DeMol, M.5
Schaeffer, P.6
-
158
-
-
77952683864
-
Gas6 is complexed to the soluble tyrosine kinase receptor Axl in human blood
-
Ekman C., Stenhoff J., Dahlback B. Gas6 is complexed to the soluble tyrosine kinase receptor Axl in human blood. J Thromb Haemost 2010, 8:838-844.
-
(2010)
J Thromb Haemost
, vol.8
, pp. 838-844
-
-
Ekman, C.1
Stenhoff, J.2
Dahlback, B.3
-
159
-
-
77955799154
-
Plasma concentrations of Gas6 (growth arrest specific protein 6) and its soluble tyrosine kinase receptor sAxl in sepsis and systemic inflammatory response syndromes
-
Ekman C., Linder A., Akesson P., Dahlback B. Plasma concentrations of Gas6 (growth arrest specific protein 6) and its soluble tyrosine kinase receptor sAxl in sepsis and systemic inflammatory response syndromes. Crit Care 2010, 14:R158.
-
(2010)
Crit Care
, vol.14
-
-
Ekman, C.1
Linder, A.2
Akesson, P.3
Dahlback, B.4
-
160
-
-
82955249066
-
Elevated plasma Gas6 levels are associated with venous thromboembolic disease
-
Blostein M.D., Rajotte I., Rao D.P., Holcroft C.A., Kahn S.R. Elevated plasma Gas6 levels are associated with venous thromboembolic disease. J Thromb Thrombolysis 2011, 32:272-278.
-
(2011)
J Thromb Thrombolysis
, vol.32
, pp. 272-278
-
-
Blostein, M.D.1
Rajotte, I.2
Rao, D.P.3
Holcroft, C.A.4
Kahn, S.R.5
-
161
-
-
0037097589
-
Arp2/3 complex is required for actin polymerization during platelet shape change
-
Li Z., Kim E.S., Bearer E.L. Arp2/3 complex is required for actin polymerization during platelet shape change. Blood 2002, 99:4466-4474.
-
(2002)
Blood
, vol.99
, pp. 4466-4474
-
-
Li, Z.1
Kim, E.S.2
Bearer, E.L.3
-
162
-
-
12444303861
-
Accumulation of tissue factor into developing thrombi in vivo is dependent upon microparticle P-selectin glycoprotein ligand 1 and platelet P-selectin
-
Falati S., Liu Q., Gross P., Merrill-Skoloff G., Chou J., Vandendries E., et al. Accumulation of tissue factor into developing thrombi in vivo is dependent upon microparticle P-selectin glycoprotein ligand 1 and platelet P-selectin. J Exp Med 2003, 197:1585-1598.
-
(2003)
J Exp Med
, vol.197
, pp. 1585-1598
-
-
Falati, S.1
Liu, Q.2
Gross, P.3
Merrill-Skoloff, G.4
Chou, J.5
Vandendries, E.6
-
163
-
-
0033574172
-
Recombinant soluble form of PSGL-1 accelerates thrombolysis and prevents reocclusion in a porcine model
-
Kumar A., Villani M.P., Patel U.K., Keith J.C., Schaub R.G. Recombinant soluble form of PSGL-1 accelerates thrombolysis and prevents reocclusion in a porcine model. Circulation 1999, 99:1363-1369.
-
(1999)
Circulation
, vol.99
, pp. 1363-1369
-
-
Kumar, A.1
Villani, M.P.2
Patel, U.K.3
Keith, J.C.4
Schaub, R.G.5
-
164
-
-
38749140235
-
Characterization of the novel P-selectin inhibitor PSI-697 [2-(4-chlorobenzyl)-3-hydroxy-7,8,9,10-tetrahydrobenzo[h] quinoline-4-carboxylic acid] in vitro and in rodent models of vascular inflammation and thrombosis
-
Bedard P.W., Clerin V., Sushkova N., Tchernychev B., Antrilli T., Resmini C., et al. Characterization of the novel P-selectin inhibitor PSI-697 [2-(4-chlorobenzyl)-3-hydroxy-7,8,9,10-tetrahydrobenzo[h] quinoline-4-carboxylic acid] in vitro and in rodent models of vascular inflammation and thrombosis. J Pharmacol Exp Ther 2008, 324:497-506.
-
(2008)
J Pharmacol Exp Ther
, vol.324
, pp. 497-506
-
-
Bedard, P.W.1
Clerin, V.2
Sushkova, N.3
Tchernychev, B.4
Antrilli, T.5
Resmini, C.6
-
165
-
-
38949147126
-
Prophylactic P-selectin inhibition with PSI-421 promotes resolution of venous thrombosis without anticoagulation
-
Meier T.R., Myers D.D., Wrobleski S.K., Zajkowski P.J., Hawley A.E., Bedard P.W., et al. Prophylactic P-selectin inhibition with PSI-421 promotes resolution of venous thrombosis without anticoagulation. Thromb Haemost 2008, 99:343-351.
-
(2008)
Thromb Haemost
, vol.99
, pp. 343-351
-
-
Meier, T.R.1
Myers, D.D.2
Wrobleski, S.K.3
Zajkowski, P.J.4
Hawley, A.E.5
Bedard, P.W.6
-
166
-
-
2942546273
-
Release of soluble CD40L from platelets is regulated by glycoprotein IIb/IIIa and actin polymerization
-
Furman M.I., Krueger L.A., Linden M.D., Barnard M.R., Frelinger A.L., Michelson A.D. Release of soluble CD40L from platelets is regulated by glycoprotein IIb/IIIa and actin polymerization. J Am Coll Cardiol 2004, 43:2319-2325.
-
(2004)
J Am Coll Cardiol
, vol.43
, pp. 2319-2325
-
-
Furman, M.I.1
Krueger, L.A.2
Linden, M.D.3
Barnard, M.R.4
Frelinger, A.L.5
Michelson, A.D.6
-
167
-
-
0037456769
-
Soluble CD40 ligand in acute coronary syndromes
-
Heeschen C., Dimmeler S., Hamm C.W., van den Brand M.J., Boersma E., Zeiher A.M., Simoons M.L. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 2003, 348:1104-1111.
-
(2003)
N Engl J Med
, vol.348
, pp. 1104-1111
-
-
Heeschen, C.1
Dimmeler, S.2
Hamm, C.W.3
van den Brand, M.J.4
Boersma, E.5
Zeiher, A.M.6
Simoons, M.L.7
-
168
-
-
77954962134
-
New steroidal glycosides isolated as CDL inhibitors of activated platelets
-
Chen H., Ou W., Wang G., Wang N., Zhang L., Yao X. New steroidal glycosides isolated as CDL inhibitors of activated platelets. Molecules 2010, 15:4589-4598.
-
(2010)
Molecules
, vol.15
, pp. 4589-4598
-
-
Chen, H.1
Ou, W.2
Wang, G.3
Wang, N.4
Zhang, L.5
Yao, X.6
|